期刊文献+

HPLC测定盐酸苯海索中杂质3-苯基-1-(哌啶-1-基)戊-3-醇盐酸盐

Determination of 3-Phenyl-1-(Piperidin-1-yl) Pentan-3-Ol Hydrochloride in Trihexyphenidyl Hydrochloride by HPLC
下载PDF
导出
摘要 目的建立高效液相色谱法测定盐酸苯海索中杂质3-苯基-1-(哌啶-1-基)戊-3-醇盐酸盐的含量。方法用十八烷基硅烷键合硅胶为填充剂;以0.1%三乙胺溶液(用磷酸调节pH值至4.0)-乙腈(70∶30)为流动相;检测波长为210 nm;流速为每分钟1.0 mL。结果在此色谱条件下,盐酸苯海索中杂质3-苯基-1-(哌啶-1-基)戊-3-醇盐酸盐分析方法专属性、精密度、耐用性、稳定性均良好。结论经过方法学验证,该方法适用于盐酸苯海索中杂质3-苯基-1-(哌啶-1-基)戊-3-醇盐酸盐含量的测定。 Objective To establish a HPLC method for determination of impurity 3-phenyl-1-(piperidin-1-yl) pentan-3-ol hydrochloride in trihexyphenidyl hydrochloride. Methods A C18 column, 0.1 % triethylamine(adjust with phosphoric acid to a pH of 4.0)-Acetonitrile(70:30) as mobile phase, 210 nm as detection wavelength, and 1.0 mL·min-1 as flow rate were used. Results: The method showed good specificity, precision, durability and stability under above chromatographic condition. Conclusion The method is suitable for the determination of impurity 3-phenyl-1-(piperidin-1-yl) pentan-3-ol hydrochloride in trihexyphenidyl hydrochloride through the methodology validation.
作者 贝红霞 梁中卫 孔凯丽 丁爱忠 Bei Hongxia;Liang Zhongwei;Kong Kaili;Ding Aizhong(Preparation Technology Office Jiangsu Tasly Diyi Pharmaceutical Co.,Ltd.,Huaian 223003,China)
出处 《广东化工》 CAS 2020年第17期171-172,共2页 Guangdong Chemical Industry
关键词 3-苯基-1-(哌啶-1-基)戊-3-醇盐酸盐 杂质 盐酸苯海索 高效液相色谱法 3-phenyl-1-(piperidin-1-yl)pentan-3-ol hydrochloride impurity trihexyphenidyl hydrochloride HPLC
  • 相关文献

参考文献5

二级参考文献54

  • 1周玉萍,魏秋菊,闫珉.硫酸亚铁预防氯丙嗪致锥体外系反应的效果[J].临床精神医学杂志,2004,14(4):223-224. 被引量:3
  • 2方贻儒,王祖承,黄继忠,谢斌,王士清,苏炳华,蔡秋艳.苯海索(安坦)与抗精神病药有必要长期合用吗[J].上海精神医学,1994,6(3):129-132. 被引量:21
  • 3杨颖琳,史美甫.帕金森病的药物治疗[J].中国药业,2005,14(12):19-22. 被引量:19
  • 4江开达 罗星光 等.门诊精神药物使用情况的调查[J].临床精神医学,1998,4:234-234.
  • 5赵振元.抗胆碱药物的用药时间与锥体外系反应的关系[J].四川精神卫生,1994,7:117-117.
  • 6Tetrud JW, Koller WC. A novel formulation of selegiline for the treatment of Parkinson's disease [ J ]. Neurology, 2004, 12 ( 63 7suppl2): s2 - 6.
  • 7Evidente VG, Adler CH, Caviness JN, et al. A pilot study on the moter effects of rimantadine in parkinson's disease [ J ]. Clin Neurophamacol,1999, 22(1): 30.
  • 8Fernandez HH, Trischmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations [ J ]. Drug Saf, 2003, 26 ( 9 ):643.
  • 9Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease[J]. Mov Disord, 2004, 19(1):29.
  • 10Morggante L, Epifanio A, Spina E, et al. Quetiapine and cloazpine in parkinsonian patients with dopaminergic psychosis [ J ]. Rev Neurol, 2004,39(7): 661.

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部